ReviewInternational journal of molecular sciences2020
Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Metabolomic Profiles of Inflammation Associated With Incident Ischemic Stroke Risk in Women.Neurology · 2026Article
- Distribution of gut microbiota and prognostic value in elderly patients with coronary atherosclerosis: a preliminary culture-based study.BMC cardiovascular disorders · 2026Article
- Gut microbiota dysbiosis-induced chronic inflammation as a driver of atherosclerosis: cellular crosstalk and host-microbe interactions.Frontiers in cellular and infection microbiology · 2026Review
- The Gut Microbiota-NLRP3 Inflammasome Axis in Chronic Heart Failure: Mechanisms Across Heart Failure Phenotypes and Therapeutic Perspectives.Journal of inflammation research · 2026Review
- Polyphenol-Microbiota Interactions in Atherosclerosis: The Role of Hydroxytyrosol and Tyrosol in Modulating Inflammation and Oxidative Stress.Nutrients · 2025Review
- Understanding the Relationship Between Cerebrovascular Disease and the Gut Microbiome.Stroke (Hoboken, N.J.) · 2025Review
- The interaction of inflammasomes and gut microbiota: novel therapeutic insights.Cell communication and signaling : CCS · 2024Review
- The interaction between oral microbiota and gut microbiota in atherosclerosis.Frontiers in cardiovascular medicine · 2024Review
- Periodontal bacteria influence systemic diseases through the gut microbiota.Frontiers in cellular and infection microbiology · 2024Review
- Multi-omics in exploring the pathophysiology of diabetic retinopathy.Frontiers in cell and developmental biology · 2024Review
- Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship.International journal of molecular sciences · 2023Review
- Markers of immune dysregulation in response to the ageing gut: insights from aged murine gut microbiota transplants.BMC gastroenterology · 2022Article
- Tackling Atherosclerosis via Selected Nutrition.International journal of molecular sciences · 2022Review
- Research progress on Th17 and T regulatory cells and their cytokines in regulating atherosclerosis.Frontiers in cardiovascular medicine · 2022Review
- Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis.Journal of clinical medicine · 2021Review
- Ultra-processed Foods and Cardiovascular Diseases: Potential Mechanisms of Action.Advances in nutrition (Bethesda, Md.) · 2021Review
- Immunopathology of Atherosclerosis and Related Diseases: Focus on Molecular Biology.International journal of molecular sciences · 2021Article
- The Microbiome and Its Implications in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is the key for the initiation and progression of atherosclerosis. Accumulating evidence has revealed that an altered gut microbiome (dysbiosis) triggers both local and systemic inflammation to cause chronic inflammatory diseases, including atherosclerosis. There have been some microbiome-relevant pro-inflammatory mechanisms proposed to link the relationships between dysbiosis and atherosclerosis such as gut permeability disruption, trigger of innate immunity from lipopolysaccharide (LPS), and generation of proatherogenic metabolites, such as trimethylamine N-oxide (TMAO). Meanwhile, immune responses, such as inflammasome activation and cytokine production, could reshape both composition and function of the microbiota. In fact, the immune system delicately modulates the interplay between microbiota and atherogenesis. Recent clinical trials have suggested the potential of immunomodulation as a treatment strategy of atherosclerosis. Here in this review, we present current knowledge regarding to the roles of microbiota in contributing atherosclerotic pathogenesis and highlight translational perspectives by discussing the mutual interplay between microbiota and immune system on atherogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.